ABIONYX Pharma SA (CEREN):企業の財務・戦略的SWOT分析

◆英語タイトル:ABIONYX Pharma SA (CEREN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH140130FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥64,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥97,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ABIONYX Pharma SA (ABIONYX) is a biopharmaceutical company that discovers and develops HDL therapies for the treatment of cardiovascular and metabolic diseases. Its therapies include CER-001 a negatively-charged lipoprotein particle that find application in atheosclerotic plaque regression; and CER-209 is a simulator of HDL receptors. The company develops a portfolio of HDL therapies including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as patients with HDL deficiency, and post-ACS patients. It also develops drugs that increase HDL for patients with low number of HDL particles to treat atherosclerosis and related metabolic diseases. ABIONYX works in partnership with other research and biotechnology companies for the development of HDL drug delivery products and technologies. The company has presence in France and the US. Cerenis is headquartered in France.

ABIONYX Pharma SA Key Recent Developments

Feb 25,2021: ABIONYX Pharma: annual results 2020
Feb 04,2021: ABIONYX Pharma provides an update on its cash position and the start of its clinical activities in Q4 2020
Oct 22,2020: ABIONYX announces its cash position and provides an activity update for the 3rd quarter 2020
Sep 10,2020: ABIONYX Pharma: 2020 Half-year results
Apr 23,2020: Gross cash position and business review for the first quarter of 2020

This comprehensive SWOT profile of ABIONYX Pharma SA provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of ABIONYX Pharma SA including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

ABIONYX Pharma SA – Key Information
ABIONYX Pharma SA – Overview
ABIONYX Pharma SA – Key Employees
ABIONYX Pharma SA – Key Employee Biographies
ABIONYX Pharma SA – Key Operational Heads
ABIONYX Pharma SA – Major Products and Services
ABIONYX Pharma SA – History
ABIONYX Pharma SA – Company Statement
ABIONYX Pharma SA – Locations And Subsidiaries
ABIONYX Pharma SA
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

ABIONYX Pharma SA – Business Description
ABIONYX Pharma SA – Corporate Strategy
ABIONYX Pharma SA – SWOT Analysis
SWOT Analysis – Overview
ABIONYX Pharma SA – Strengths
ABIONYX Pharma SA – Weaknesses
ABIONYX Pharma SA – Opportunities
ABIONYX Pharma SA – Threats
ABIONYX Pharma SA – Key Competitors

Section 3 – Company Financial Performance Charts

ABIONYX Pharma SA – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

ABIONYX Pharma SA, Key Information
ABIONYX Pharma SA, Key Ratios
ABIONYX Pharma SA, Share Data
ABIONYX Pharma SA, Major Products and Services
ABIONYX Pharma SA, History
ABIONYX Pharma SA, Key Employees
ABIONYX Pharma SA, Key Employee Biographies
ABIONYX Pharma SA, Key Operational Heads
ABIONYX Pharma SA, Other Locations
ABIONYX Pharma SA, Subsidiaries
ABIONYX Pharma SA, Key Competitors
ABIONYX Pharma SA, SWOT Analysis
ABIONYX Pharma SA, Ratios based on current share price
ABIONYX Pharma SA, Annual Ratios
ABIONYX Pharma SA, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[ABIONYX Pharma SA (CEREN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • 3I Group Plc
    3I Group Plc - Strategy, SWOT and Corporate Finance Report Summary 3I Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Sasol Ltd (SOL):石油・ガス:M&Aディール及び事業提携情報
    Summary Sasol Ltd (Sasol) is an integrated energy and chemicals company. It develops and commercializes technologies; and builds and operates facilities to produce a range of products, including liquid fuels, chemicals, and low-carbon electricity. The company’s product offerings include olefins and …
  • East-Central Iowa Rural Electric Cooperative:発電所・企業SWOT分析
    East-Central Iowa Rural Electric Cooperative - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, inf …
  • CytomX Therapeutics Inc (CTMX):製薬・医療:M&Aディール及び事業提携情報
    Summary CytomX Therapeutics Inc (CytomX) is a clinical-stage biopharmaceutical company which develops novel therapeutic antibodies and Probody therapeutics for the treatment of cancer. The company’s leading product candidates include CX-072, CX-2009, BMS-986249, CX-2029, CX-188, probody drug conjuga …
  • The Tinplate Company of India Limited:企業の戦略・SWOT・財務情報
    The Tinplate Company of India Limited - Strategy, SWOT and Corporate Finance Report Summary The Tinplate Company of India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • XPO Logistics, Inc.:企業の戦略・SWOT・財務分析
    XPO Logistics, Inc. - Strategy, SWOT and Corporate Finance Report Summary XPO Logistics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • TOLMAR Inc-製薬・医療分野:企業M&A・提携分析
    Summary TOLMAR Inc (TOLMAR), a subsidiary of Tolmar Holding Inc is a developer, manufacturer and distributor of pharmaceutical products. The company provides generic dermatology products such as creams, gels, ointments and solutions. It also provides levetiracetam oral solutions including antiepilep …
  • JGC Corporation (1963):電力:M&Aディール及び事業提携情報
    Summary JGC Corporation (JGC) is an engineering contracting company. It offers engineering, procurement and construction services for various engineering contracts and projects in the areas of oil and gas development, petroleum refining, natural gas processing, petrochemicals, clean energy and power …
  • AirStrip Technologies Inc-医療機器分野:企業M&A・提携分析
    Summary AirStrip Technologies Inc (AirStrip) is a healthcare solution provider that offers medical software solutions and services. The company offers mobile interoperability platform, accelerator services and wireless maternal-fetal monitoring solutions. It caters its products to healthcare provide …
  • Sunrise Medical (US) LLC:企業の戦略的SWOT分析
    Sunrise Medical (US) LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • VocaLink Limited:企業の戦略・SWOT・財務情報
    VocaLink Limited - Strategy, SWOT and Corporate Finance Report Summary VocaLink Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Cocoon Holdings Ltd (428):企業の財務・戦略的SWOT分析
    Cocoon Holdings Ltd (428) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Singulus Technologies AG (SNG):企業の財務・戦略的SWOT分析
    Summary Singulus Technologies AG (Singulus Technologies) is an optical disc production line manufacturer that develops technologies for efficient and resource-conserving production processes. The company offers optical disc solutions such as blu-ray disc, CD, and DVD production equipment. Its solar …
  • Lanna Resources Public Company Limited:企業の戦略・SWOT・財務情報
    Lanna Resources Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Lanna Resources Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Andritz AG (ANDR):企業の財務・戦略的SWOT分析
    Andritz AG (ANDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Paramount Resources Ltd (POU):企業の財務・戦略的SWOT分析
    Summary Paramount Resources Ltd (Paramount Resources) is an energy company that offers exploration, production, development, and marketing of oil and gas products. The company offers products such s crude oil, fuel oil, natural gas and natural gas liquids. It operates in three segments such as princ …
  • Ecrins Therapeutics SAS-製薬・医療分野:企業M&A・提携分析
    Summary Ecrins Therapeutics SAS (Ecrins) is a biotechnology company that discovers and develops small molecule drug candidates against several oncology indications in humans and domestic animals. The company provides products such as native and labeled tubulin, tubulin polymerization kit and monoclo …
  • PT Rekayasa Industri:企業の戦略的SWOT分析
    PT Rekayasa Industri - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • SciClone Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary SciClone Pharmaceuticals Inc (SciClone), a subsidiary of Silver Biotech Investment Ltd, develops and commercializes products for the treatment of cancer, cardiovascular disorders and infectious diseases. The company’s lead product, Zadaxin (thymalfasin) is an immunostimulatory agent indicate …
  • B&G Foods, Inc.:企業のM&A・事業提携・投資動向
    B&G Foods, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's B&G Foods, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆